Enanta Pharmaceuticals | Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Amgen USD 539M 1000K 2025-12
Anika Therapeutics USD 143K 1000 2025-03
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 1.16B 2025-09
BioCryst Pharmaceuticals USD 1.9M 3K 2023-09
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 0 2025-09
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Halozyme Therapeutics USD 117.52M 98K 2025-09
Heron Therapeutics USD 1.52M 14K 2024-09
Immunic USD 8K 4K 2024-06
Incyte USD 196.13M 2.01M 2025-09
Insmed USD 212.58M 210.76M 2025-09
Ionis Pharmaceuticals USD 161.14M 160.98M 2025-09
J&J USD 2.41B 584K 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
Ligand Pharmaceuticals USD 20K 0 2025-03
Merck USD 2.49B 15.79M 2025-09
Neurocrine Biosciences USD 99.7M 700K 2025-09
Novartis USD 1.94B 23.4M 2025-06
Novavax USD 1.62M 211K 2024-09
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 79.93M 554K 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.77M 7.06M 2025-09
Vertex Pharmaceuticals USD 254M 2.29M 2025-09


Enanta Pharmaceuticals Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.